TAC_Sp
☆    

Spain,
2014-04-04 15:39
(4046 d 18:24 ago)

Posting: # 12770
Views: 3,646
 

 Cross over BE study with four periods [Two-Stage / GS Designs]

Hello,

We have conducted a randomized, sequential and crossover trial of two formulations for nasal inhalation in a pressurized container with 18 healthy volunteers. The test drug and the reference drug were administered both with and without inhalation chamber, which represents four experimental periods. Randomization of the form of administration was conducted (Test with chamber / Reference without chamber / Reference with chamber / Test without chamber), so that the 18 subjects completed the four periods.

The objective of the first stage was to obtain the necessary data to calculate the final sample size.

Once finished the first stage, the statistical analysis resulted on different CV intra for each form of administration with and without chamber, (29% and 35% respectively). So, finally 36 and 60 volunteers respectively should be added in in the second stage.

Would it be necessary to complete the second stage with 60 subjects for both forms of administration? or could we reduce to 36 subjects in the case of chamber?

Thanks,

Kind regards.
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2014-04-04 16:20
(4046 d 17:42 ago)

@ TAC_Sp
Posting: # 12773
Views: 2,965
 

 Cross over BE study with four periods

¡Hola Armando!

IMHO you were courageous performing this study, since no Two-Stage method for such a design is published (currently only 2×2 cross-over and parallel). Did you perform simulations in order to demonstrate that the patient’s risk is maintained?

❝ […] so that the 18 subjects completed the four periods.


In the randamization you needed a multiple of 4. Just to clarify: There were two drop-outs?

❝ Once finished the first stage, the statistical analysis resulted on different CV intra for each form of administration with and without chamber, (29% and 35% respectively). So, finally 36 and 60 volunteers respectively should be added in in the second stage.


More information, please. Did you completely randomize subjects (4 sequences) or did you “stack” two 2×2 cross-overs? For details see beman’s post.

❝ Would it be necessary to complete the second stage with 60 subjects for both forms of administration? or could we reduce to 36 subjects in the case of chamber?


If you used beman’s stacked 2×2 cross-overs, the second stage could be of different sizes. If you used full randomization, no idea. IMHO, that would require simulations – which should have been performed before submitting the protocol.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
169 visitors (0 registered, 169 guests [including 9 identified bots]).
Forum time: 10:03 CEST (Europe/Vienna)

If you tell the truth you don’t have to remember anything.    Mark Twain

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5